The U.S. Food and Drug Administration ( FDA ) had until Wednesday to provide a court-ordered update on its proposed review of the chemical abortion drug mifepristone, an evaluation that would form the basis for a separate Texas lawsuit against the agency.
Mifepristone, one of two chemicals used in chemical miscarriages in addition to misoprostol, is still approved by the FDA for online purchase and delivery, which is already prohibited in Texas.
It has continued to be a source of conflict between his leadership and his pro-life basic despite President Donald Trump’s campaign promise to do so thoroughly and the agency’s protocols surrounding its sale. The former claims that the FDA has not yet completed its top-to-bottom overview of the drug, noting that it has since approved a second generic type of mifepristone.
Before leaving the organization in May, former FDA Commissioner Marty Makary was criticized specifically for supposedly” slow-walking” the drug review. At her confirmation hearing before the U.S. Senate, Dr. Heidi Overton, the new FDA director candidate, recently stated that the research had “be conducted in the most durable, academic method possible and the results must be communicated openly.”
The FDA was fined$ 20,000 by the State of Louisiana for allowing the shipment of chemical contraception pills to that position in October 2025. The lawsuit claimed that the FDA’s removal of the in-person dispensing requirement in 2023 increased the risk for women who ingest the pills without medical supervision and made it easier for abusers to sue.
During the presidency of Barack Obama, the FDA changed four Risk Evaluation and Mitigation Strategy criteria, making the most significant change in national distributing convention in 2016. It reduced the number of in-person business visits to one, made it easier for non-doctors to administer the medication, and eliminated non-fatal adverse events reporting. It also raised the gestational age of the fetus to 70 days.
Under the Biden administration, a second change occurred in 2021 when the FDA announced that mail-verification may be permitted as part of its police choice. The FDA eventually abolished the in-person need for medication dispensing in 2023.
In April, a federal district court in Louisiana ordered the FDA to release the matter by October 7 and halted the case. The U.S. 5th Circuit Court of Appeals, which includes Texas, Louisiana, and Mississippi, filed an appeal to reinstate mifepristone’s in-person administering needs, which the court granted. Following two companies of the biochemical abortion drugs ‘ claims that the decision was “unprecedented,” the U.S. Supreme Court finally halted this order.
The U.S. District Court for the Northern District of Texas requested a pause in the case until either the FDA’s review of mifepristone is finished, or the deadline of December 1 ( or the first ), according to Judge ReedO’Connor of the U.S. District Court for the Northern District of Texas.
By the time of release, The Texan’s request for comment had been returned.
At his confirmation hearing earlier this year over the FDA mifepristone review, U.S. Senator John Cornyn (R-TX ), who has repeatedly pressed him over the Louisiana litigation, has repeatedly asked him to resolve the controversy.
This ought to be a very simple decision, Cornyn said, eventually choosing Blanche over President Trump, who is the most pro-life leader.
